G
Guillermo Garcia-Manero
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1611
Citations - 52621
Guillermo Garcia-Manero is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Myelodysplastic syndromes. The author has an hindex of 108, co-authored 1411 publications receiving 43103 citations. Previous affiliations of Guillermo Garcia-Manero include Sapporo Medical University & University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate‐1 risk myelodysplastic syndrome
Sophie Dimicoli,Elias Jabbour,Gautam Borthakur,Tapan M. Kadia,Zeev Estrov,Hui Yang,Mary A. Kelly,Sherry Pierce,Hagop M. Kantarjian,Guillermo Garcia-Manero +9 more
TL;DR: Data indicates that panobinostat at the dose and schedule studied here has limited activity in lower risk MDS, and does not consistently induce histone acetylation as measured with Western blot.
Journal ArticleDOI
MYBL2 is a sub-haploinsufficient tumor suppressor gene in myeloid malignancy
Stefan Heinrichs,Lillian F. Conover,Carlos E. Bueso-Ramos,Outi Kilpivaara,Kristen E. Stevenson,Donna Neuberg,Mignon L. Loh,Wen Shu Wu,Scott J. Rodig,Guillermo Garcia-Manero,Hagop M. Kantarjian,A. Thomas Look +11 more
TL;DR: It is concluded that downregulation of MYBL2 activity below levels predicted by classical haploinsufficiency underlies the clonal expansion of hematopoietic progenitors in a large fraction of human myeloid malignancies.
Journal ArticleDOI
Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)
Azra Raza,Naomi Galili,Deborah Mulford,Scott E. Smith,Gail L. Brown,David P. Steensma,Roger M. Lyons,Ralph V. Boccia,Mikkael A. Sekeres,Guillermo Garcia-Manero,Ruben A. Mesa +10 more
TL;DR: The tolerability and activity profile of eZatiostat co-administered with lenalidomide supports the further development of ezatiostats in combination with len Khalidomide in MDS and also encourages studies of this combination in other hematologic malignancies where lenalidumide is active.
Journal ArticleDOI
An Open-Label, Phase 2, Dose-Finding Study of Sotatercept (ACE-011) in Patients with Low or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndromes (MDS) or Non-Proliferative Chronic Myelomonocytic Leukemia (CMML) and Anemia Requiring Transfusion
Rami S. Komrokji,Guillermo Garcia-Manero,Lionel Ades,Abderrahmane Laadem,Bond Vo,Thomas Prebet,Aspasia Stamatoullas,Thomas E. Boyd,Jacques Delaunay,David P. Steensma,Mikkael A. Sekeres,Odile Beyne-Rauzy,Jun Zou,Kenneth M. Attie,Matthew L. Sherman,Pierre Fenaux,Alan F. List +16 more
TL;DR: This phase 2, open-label, dose-finding study to determine a safe, tolerable, and effective dose of sotatercept resulting in erythroid hematological improvement in patients with anemia and IPSS-defined Low or Int-1-risk MDS was generally well tolerated.
Journal ArticleDOI
Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide
Alireza Eghtedar,Ildefonso Rodriguez,Hagop M. Kantarjian,Susan O'Brien,Naval Daver,Guillermo Garcia-Manero,Alessandra Ferrajoli,Tapan M. Kadia,Sherry Pierce,Jorge E. Cortes,Farhad Ravandi +10 more
TL;DR: Treatment of patients with APL using the non-chemotherapy regimen of ATRA plus ATO is not associated with a higher incidence of secondary cancers adjusted for unit time of exposure.